Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. - Wikidata - awgldk - TriplyDB

Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

http://www.wikidata.org/entity/Q33749707

about

Management of trypanosomiasis and leishmaniasis VNI cures acute and chronic experimental Chagas disease Immunosuppression and Chagas disease: a management challenge Antitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite Growth 4-Aminopyridyl-Based CYP51 Inhibitors as Anti- Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 High throughput screening for anti-Trypanosoma cruzi drug discovery Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.Methodological advances in drug discovery for Chagas disease.Current and developing therapeutic agents in the treatment of Chagas disease Drug strategies targeting CYP51 in neglected tropical diseases Would selenium supplementation aid in therapy for Chagas disease?Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole.Genome profiling of sterol synthesis shows convergent evolution in parasites and guides chemotherapeutic attack.Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design.Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.Chagas heart disease: report on recent developments.Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives.Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi.Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51)Advances in Chagas disease drug development: 2009-2010 In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.Cellular response to Trypanosoma cruzi infection induces secretion of defensin α-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection.Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease.Current status of Chagas disease chemotherapy.Guidelines on the treatment of chronic coinfection by Trypanosoma cruzi and HIV outside endemic areas.The emerging role of amiodarone and dronedarone in Chagas disease.Epidemiology of Chagas disease in Europe: many calculations, little knowledge.An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients.Therapeutical approaches under investigation for treatment of Chagas disease.Chagas disease drug discovery: toward a new era.Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.

P2860

Q24596889-850605F0-E70A-481E-B833-0EECE51345F2 Q24604994-192CF3E5-CC47-4925-8B69-DEB176B8E0AA Q26863357-A6F7D376-0F31-428E-9401-E9B714810745 Q27676649-256751B1-DC9C-473B-BD1D-F75AA986A225 Q27684956-693E77A9-A64E-4FCD-B41B-C698E26EB28B Q28476774-EC4DDA07-67A2-4D68-9514-B4EE67FFE5E6 Q28481694-A0085851-B8D3-4FF9-A4BA-C50230ED7124 Q28542489-61BC29E0-F402-468A-8418-0D6D7F3F4C55 Q28542767-158FF572-9346-4E8E-927D-7BF78D4AD2BB Q28546644-61814EE7-FDBD-4517-B83C-0AE1C75C6C9E Q28548320-3344F470-BBB5-4A23-BAD1-3F64103234C9 Q28727454-92399BD2-B47B-4EC9-A30C-49E99E0BB5A9 Q33876638-9E72016B-A6D9-49A8-98A0-3E3719B62587 Q33945347-3567EA5C-9AA5-4F39-93AF-CC0A57D39707 Q34170132-67A28483-B353-4BF2-93DE-EB90DC858BE0 Q34622554-EE086F43-48E5-4F45-8972-8A213F1AC66F Q34629025-3E366DC5-2A7A-4041-B4C3-90337F40A31E Q34737833-2F696878-819B-4A9B-AB95-D299CD421AEF Q35120349-A10B70C7-A6E8-4C60-9F9D-C14D3E58CAE9 Q35163073-425D4EFB-1C62-49ED-B562-367297A68F4C Q35367533-D1308701-2D28-4BAF-A015-BFBA5D535933 Q35745413-9E2959D6-4662-45A1-A63C-D91430511AD4 Q35810790-3AEB34D2-5F82-463B-A40D-E156C175A39B Q35859935-752256C2-AC57-41DF-94BF-FA1BADC36862 Q36170517-DF159308-4C0F-4F78-865A-AC2463BCCB65 Q36276857-3C5E9E90-7EAE-44F7-98BF-BA92ADB1F8D7 Q36368984-D35B60DA-A4E6-469B-9E1E-D18863DEE9D7 Q36702159-43CB3EEC-E821-4C4F-9610-6DFFC00FE2F9 Q37124209-86061DD0-E796-4935-ACEE-4F8D2294914D Q37264811-7355264B-2FF2-4128-B74B-524B811DC1BF Q37401820-F9EF6CF7-CD3A-4AA2-98C9-5F08205D145A Q37730358-3781EF30-1119-4695-9595-1B1ABB00D546 Q37879205-65C74439-F4CB-4CF9-83A0-2E5A2A905C82 Q37970541-73964CE0-9AC9-4523-BC00-89360794407C Q38032507-661065FA-9678-4B83-9C14-508F0D478C21 Q38132635-F8580DC5-E9BB-4038-97CF-6684575906EA Q38183905-EFAB16F6-C974-45FF-AA60-541631A557CB Q38214136-139D6499-CDCE-4098-B17E-7BC486D4CA74 Q38253281-2E1E4DD1-B6C4-43B5-9A8E-578E1721E78D Q38256874-111BFD67-08F8-4CCC-BF8A-5F8C8CFCA93E

P2860

Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

http://www.wikidata.org/entity/Q33749707

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Successful treatment with posa ...... systemic lupus erythematosus.

@ast

Successful treatment with posa ...... systemic lupus erythematosus.

@en

type

label

Successful treatment with posa ...... systemic lupus erythematosus.

@ast

Successful treatment with posa ...... systemic lupus erythematosus.

@en

prefLabel

Successful treatment with posa ...... systemic lupus erythematosus.

@ast

Successful treatment with posa ...... systemic lupus erythematosus.

@en

P1433

Q33749707-DFFE178C-12C3-4B2A-9C40-627BF80EF673

P1476

Q33749707-46CF646C-2027-4FE2-9136-8E5E15AD0E11

P2093

Q33749707-0DA2335C-4283-4B38-A4B7-98C73A6A5586

Q33749707-68052FEA-7AE7-4237-8AEF-C119E614F886

Q33749707-837CBBF6-5D20-4EA9-A218-43D59D799FFB

P2860

Q33749707-0DBBD981-5C86-4033-856C-FF4E00D5B881

Q33749707-13829218-B86A-429F-803E-3490E8EEC200

Q33749707-28AD2096-9340-4472-A507-FB768244976F

Q33749707-316FB5EB-3D24-485C-932C-636E99C440C6

Q33749707-33E7BD87-1487-473F-A49C-A59662499A85

Q33749707-3876A7E5-1679-478B-B22D-D52412306EC5

Q33749707-427C65BA-28C5-4F7C-8649-2FCFF1848C93

Q33749707-52EB3272-E5D0-4B5F-9D27-B28EEA622007

Q33749707-5459C5DF-A6D3-4606-91A6-3C0674D09042

Q33749707-54BC76A0-5A24-4732-A9D7-A7E8B35B4E96

P304

Q33749707-57DDB63D-3E78-45BC-B990-8D337B0E61FC

P31

Q33749707-A689B463-108E-4C59-B9F3-A5C3527F5BB3

Q33749707-e0560f61-e902-4145-aa4b-1eab0ec266df

P356

Q33749707-587BD48B-3AEB-47E6-A9CB-89371E58D815

P407

Q33749707-645057BF-6B48-490C-9CF7-37136AEB2F7C

P433

Q33749707-1ED1890E-9923-47A1-9496-A9BE8BAF01B2

P478

Q33749707-A7405543-9142-4F9F-B14E-462382F96B14

P50

Q33749707-34F6CE4D-CBEB-45BF-9458-4FFA5E187367

Q33749707-4AA0FF2C-211F-45E8-B5D6-7758673AA6AF

Q33749707-AABB3D64-D2E0-4C7C-A0CA-83D06C914426

P5008

Q33749707-78DE85D5-6124-4BF0-A3EB-FEF446B23038

P577

Q33749707-1B71B592-10CA-4627-883C-2D360C69F10D

P5875

Q33749707-2CFBF9BA-B571-4F7C-A3B0-FB8AEA31746E

P698

Q33749707-58EDEB30-C38F-48A8-B4B5-1A4F65F60F87

P921

Q33749707-58FD20DB-1B7B-4D51-A35C-B17173D0A8BB

Q33749707-E8146AE0-26C1-4D7D-852D-4816EAE89AA4

P932

Q33749707-47CE4ABF-5E10-4486-A73B-E29DDDE9B9D1

P356

AJTMH.2010.09-0620

P1433

American Journal of Tropical Medicine and Hygiene

P1476

Successful treatment with posa ...... systemic lupus erythematosus.

@en

P2093

Julio A Urbina

http://www.w3.org/2001/XMLSchema#string

María-Jesús Pinazo

http://www.w3.org/2001/XMLSchema#string

Paulo Luis López-Chejade

http://www.w3.org/2001/XMLSchema#string

P2860

Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients

The challenges of Chagas Disease-- grim outlook or glimmer of hope.

Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.

Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

Some aspects of protozoan infections in immunocompromised patients- a review.

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease.

The impact of Chagas disease control in Latin America: a review.

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.

Specific chemotherapy of Chagas disease: controversies and advances.

P304

583-587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4269/AJTMH.2010.09-0620

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Montserrat Gállego

Joaquim Gascón

Gerard Espinosa

P5008

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42611204

http://www.w3.org/2001/XMLSchema#string

P698

20348503

http://www.w3.org/2001/XMLSchema#string

P921

P932

2844568

http://www.w3.org/2001/XMLSchema#string